Physician profile
Amy Hoffman
NPI 1053751461
$2,072.47
in general payments reported to CMS, 2019-2025
30 companies · $239 in 2025
The $239 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $863 · 2022: $339 · 2023: $197 · 2024: $433 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $780 · Education: $89.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $779.81 |
| Education | $89.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $269.01 | 2021-2025 | |
| Amgen INC. | $199.63 | 2021-2024 | Evenity, Prolia |
| Glaxosmithkline, LLC. | $158.44 | 2021-2025 | Penmenvy |
| Novo Nordisk INC | $148.47 | 2021-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $133.50 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $125.64 | 2022-2025 | Qelbree, Qelbree |
| Lilly USA, LLC | $112.97 | 2021-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $101.89 | 2021-2024 | Farxiga, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $95.42 | 2021-2024 | Trintellix |
| Abbott Laboratories | $93.31 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $89.95 | 2024 | |
| Janssen Pharmaceuticals, INC | $68.26 | 2022 | |
| Amneal Pharmaceuticals LLC | $60.37 | 2021-2023 | Unithroid |
| Biohaven Pharmaceuticals, INC. | $54.68 | 2021 | |
| Exact Sciences Corporation | $49.92 | 2023-2025 | Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $48.06 | 2023 | Azstarys |
| Axsome Therapeutics, INC. | $40.60 | 2025 | Auvelity |
| Alexion Pharmaceuticals, INC. | $28.01 | 2021 | |
| Tris Pharma INC | $22.15 | 2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $19.55 | 2021 | |
| Lundbeck LLC | $19.17 | 2024 | Rexulti |
| Ironshore Pharmaceuticals INC. | $16.44 | 2022 | |
| Astellas Pharma US INC | $16.30 | 2024 | Veozah |
| Sanofi Pasteur INC. | $16.03 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.52 | 2024 | |
| Seqirus USA INC | $14.37 | 2024 | Fluad, Flucelvax |
| Ibsa Pharma INC. | $14.02 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.95 | 2022 | |
| Genentech USA, INC. | $13.65 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $13.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.